



# The **ONLY IL-23** covered for \$0 under Medicare\*



**\*Patients may pay as low as \$0  
with Medicare Part B and  
a Medigap Supplement†**



**ILUMYA® is covered  
first-line under the  
medical benefit**



**No prior authorization  
is required‡**



Help patients pay less by speaking with  
a Field Reimbursement Manager  
**Scan to complete the Patient Enrollment  
Form at [ILUMYApro.com](https://www.ilumya.com)**

\*Secondary insurance is available through a beneficiary employee retiree program, spousal coverage, privately purchased Medigap policy, or TRICARE For Life wraparound benefits.

†Part B does not require a prior authorization, but certain plan types such as Medicare Advantage may require authorization.

# ILUMYA SUPPORT

LIGHTING THE WAY®



## BUY AND BILL

- Purchase on demand with reimbursement support
- Expedited product availability
- On-site reimbursement training for your staff



## ALTERNATE SITE OF CARE (ASOC)

- Maintain patient oversight while an ASOC takes care of the rest
- Patient care without administrative burden



Scan to learn how ILUMYA SUPPORT® helps your practice find the best access route at [ILUMYApro.com/support](https://ILUMYApro.com/support)



## INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

### CONTRAINDICATIONS

ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

### WARNINGS AND PRECAUTIONS

#### Hypersensitivity

Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

#### Infections

ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.

### Pretreatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.

### Immunizations

Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

### Adverse Reactions

The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

**Please see accompanying Full Prescribing Information.**

ILUMYA trademarks and related logos are owned or licensed to Sun Pharma group companies. All other trademarks are the property of their respective owners. © 2024 Sun Pharmaceutical Industries, Inc. All rights reserved. PM-US-ILY-2736 09/2024

